Wuhan YZY Biopharma Co.,Ltd., a leading biotechnology company, was founded in 2010. YZY has its headquarters (4000m2) with administrative functions, Antibody R&D Lab, Quality Team and Pilot Production Lines (800m2) at Biolake Wuhan,Hubei,China，and a cGMP commercial scale production faciling is under construction. Our vision is to develop new class of innovative medicines based on breakthrough discovery in molecular biology .
There are approximately 100 employees--3 of them are foreign experts ,six of them hold doctor’s degree, more than 40% hold master’s degree.
Our company is committed to anti-tumor Bispecific antibody development, of which two Bispecific antibodies have been submitted IND application in China, and several innovative drugs are in pre-clinical stage. The company has been approved three Y-BODY bispecific antibody structure platform PCT patents, four patents of molecular structure and technology，and 16 patents of domestic invention. More than 30 products and technology patents have been accepted.
As our scientists continue to investigate molecular targets to impact a broad range of human cancers, the possibility of targeting these previously "undruggable"targets with bispecific antibodies, is coming true and becoming part of new drug discovery. We wish one day we could achieve our vision ——to minimize tumor hazard and promote human health!
July.2010-- Founded in Wuhan Tongji Medical College Public Health School
Aug.2010-- Initiation of early development of bispecific antibodies
Dec.2010-- The strategic development and production of tumor therapeutic antibody was determined.
Mar. 2011-- Settled in Biolake and signed a cooperation agreement with Beckman
June. 2011-- Been approved the fourth "3551" Talents Plan
Nov. 2011-- Received "Ten Outstanding Contribution Enterprise“ award from Biolake
Dec. 2011-- Built 4000 ㎡of research and development Center
Apr. 2012-- A research center for Individualized medicine had been established
Aug. 2012-- CD133/CD3 Project obtained National Natural Science Fund
Nov. 2012-- Award for Best Innovative activities
Dec. 2012-- Built up 2 250L-GMP pilot production lines
Mar.2013-- Been elected "China Protein Drug Quality Alliance" executive Director Unit
May .2013-- Approved Strategic New Industries Cluster Project by NDRC
June. 2013-- Approved the sixth "3551" Talents Plan
Dec. 2013-- Completed HER2/CD3 and EPCAM/CD3 molecular structure confirmation
Apr. 2014-- Establishment of individualized diagnosis and treatment research center
June. 2014-- HER2/CD3 Project had been approved the "Twelfth Five " Creation of Major New drugs special
Dec. 2014-- Started to promote internal control and overall budget management
Dec. 2014-- HER2/CD3 and EPCAM/CD3 Project completed process development
Feb.2015-- HER2/CD3 project completed the third batch pilot production
Mar. 2015-- Dual-function antibody patent officially approved by USPTO
2015-- EPCAM/CD3 Project had been approved listed in the "Twelfth Five " Creation of Major New Drugs Special
2015-- Began to carry out domestic and oversea investment and business cooperation
May. 2016-- EPCAM/CD3 project completed to the provincial Bureau of CFDA
May.2016-- Got A round of investment by Pan-Lin Asset Management Co., Ltd and Shenogen Pharma Group
July .2016-- Began the construction of new complex building
Dec.2016-- Been approved by Wuhan Bureau of Commerce as a joint venture
Feb.2017-- IND application of EPCAM/CD3 accepted by CDE
Feb.2017-- The company's platform patent had been authorized by USPTO(35 target protection)
Mar.2017-- HER2/CD3 Project completed CDE review meeting
Apr.2017-- Molecular structure patents of HER2/CD3 were authorized
Apr.2017-- Been awarding "Hubei province immunization target antibody drug engineering Technology Research Center"
June.2017-- Molecular structure patents of EPCAM/CD3 were authorized
June.2017-- HER2/CD3 project and PD-L1/CD3 project approved by "Thirteen-Five" Major New Drug Creation special budget
June.2017-- Basic technology research project approved by Wuhan Science and Technology Bureau
Aug.2017-- Completed the construction of new complex building
